Observational Study to Evaluate the Safety and Effectiveness of Cimzia in Rheumatoid Arthritis and Crohn's Disease Patients When Using a Comprehensive Program of Tuberculosis Screening and Monitoring

Trial Profile

Observational Study to Evaluate the Safety and Effectiveness of Cimzia in Rheumatoid Arthritis and Crohn's Disease Patients When Using a Comprehensive Program of Tuberculosis Screening and Monitoring

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2015

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Crohn's disease; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors UCB
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Nov 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 18 Aug 2014 Planned number of patients changed from 500 to 1070 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top